Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
2.310
-0.060 (-2.53%)
At close: Apr 28, 2026, 4:00 PM EDT
2.370
+0.060 (2.60%)
Pre-market: Apr 29, 2026, 5:46 AM EDT
Lipocine Revenue
In the year 2025, Lipocine had annual revenue of $1.98M, down -82.35%. Lipocine had revenue of $1.15M in the quarter ending December 31, 2025, a decrease of -67.19%.
Revenue (ttm)
$1.98M
Revenue Growth
-82.35%
P/S Ratio
9.38
Revenue / Employee
$141,191
Employees
14
Market Cap
18.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.98M | -9.22M | -82.35% |
| Dec 31, 2024 | 11.20M | 14.05M | -492.80% |
| Dec 31, 2023 | -2.85M | -3.35M | -670.16% |
| Dec 31, 2022 | 500.00K | -15.64M | -96.90% |
| Dec 31, 2021 | 16.14M | - | - |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLPCN News
- 22 days ago - What's Going On With Lipocine Stock On Monday? - Benzinga
- 22 days ago - Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 26 days ago - Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint - Benzinga
- 26 days ago - Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression - PRNewsWire
- 7 weeks ago - Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - PRNewsWire
- 2 months ago - Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - PRNewsWire
- 3 months ago - Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 3 months ago - Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire